Can I read Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial on EtoBox?

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial by Mary O’Brien; Luis Paz-Ares; Sandrine Marreaud; Urania Dafni; Kersti Oselin; Libor Havel; Emilio Esteban; Dolores Isla; Alex Martinez-Marti; Martin Faehling; Masahiro Tsuboi; Jong-Seok Lee; Kazuhiko Nakagawa; Jing Yang; Ayman Samkari; Steven M Keller; Murielle Mauer; Nitish Jha; Rolf Stahel; Benjamin Besse; Solange Peters is a Medicine article available to read on EtoBox.

What is Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial about?

## Background: Pembrolizumab is a standard-of-care for advanced non-small-cell lung cancer (nsclc). we assessed pembrolizumab as adjuvant therapy for completely resected stage ib-iiia nsclc. ## Methods: In this randomised, triple-blind, phase 3 trial (pearls/keynote-091), patients were recruited from 196 medical centres in 29 countries. eligible patients were aged 18 years or older, with completely resected, pathologically confirmed stage ib (tumours of ≥4 cm in diameter), ii, or iiia nsclc per the american joint committee on cancer staging system (7th edition) of any histology or pd-l1 expression level, and an eastern cooperative oncology group performance status of 0 or 1; adjuvant chemotherapy was to be considered for stage ib disease and was strongly recommended for stage ii and iiia disease, according to national and local guidelines. using a central interactive voice-response system, eligible participants were randomly assigned (1:1), using a minimisation technique and stratified by disease stage, previous adjuvant chemotherapy, pd-l1 expression, and geographical region, to pembrolizumab 200 mg or placebo, both administered intravenously every 3 weeks for up to 18 cycles. par

Who reads Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial?

Author

Mary O’Brien; Luis Paz-Ares; Sandrine Marreaud; Urania Dafni; Kersti Oselin; Libor Havel; Emilio Esteban; Dolores Isla; Alex Martinez-Marti; Martin Faehling; Masahiro Tsuboi; Jong-Seok Lee; Kazuhiko Nakagawa; Jing Yang; Ayman Samkari; Steven M Keller; Murielle Mauer; Nitish Jha; Rolf Stahel; Benjamin Besse; Solange Peters

Publisher

Elsevier BV

Published

2022

Language

EN

Field

Medicine (Health Sciences)